Navigation Links
AlphaVax Announces New CMV Advisory Board
Date:1/30/2008

RESEARCH TRIANGLE PARK, N.C., Jan. 30 /PRNewswire/ -- AlphaVax has assembled its Cytomegalovirus (CMV) Advisory Board to provide expertise and advice as the company moves its CMV vaccine candidates through clinical development. To be chaired by Dr. Robert Olmsted, AlphaVax's Vice President for Research, the Board members include:

-- Mark Schleiss, MD, Professor, Associate Head for Research and the

American Legion Chair in the Department of Pediatrics and Director,

Division of Infectious Diseases, at the University of Minnesota.

-- David Bernstein, MD, Albert Sabin Professor of Pediatrics, Director,

Infectious Diseases and Director of the Gamble Program at the

Cincinnati Children's Hospital and Medical Center.

-- Robert Pass, MD, Professor, Pediatrics and Microbiology at the

University of Alabama - Birmingham.

-- Paul D. Griffiths, MD, DSc, Professor and Head of the Centre for

Virology, Division of Infection at Royal Free and University College

Medical School in London.

AlphaVax is pleased to have these distinguished researchers and clinicians in the field of cytomegalovirus provide their perspectives on advancing an alphavirus vectored CMV vaccine. "We look forward to working with our CMV Advisory Board to help design and implement post-Phase I clinical programs for assessing the potential of our CMV vaccine candidates in transplant indications, prevention of mother-to-child transmission, and prophylactic adolescent immunization," said Dr. Olmsted.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. In addition to programs in influenza and cytomegalovirus, important disease targets include cancer, HIV and a number of biodefense vaccine products. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
2. ADVENTRX Announces Consolidation of Clinical and Management Positions
3. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
4. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
5. BD Announces Results of Shareholder Votes at Annual Meeting
6. BioMed Realty Trust Announces Tax Treatment of 2007 Distributions
7. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
8. Sunnylife Global Announces Completion of Surgical Wing of Xiang Tan World Friendship Hospital
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Access Pharmaceuticals Announces $2.7 Million New Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... ... Academy of Model Aeronautics (AMA), the nation’s leading voice ... systems (UAS), are launching a joint program to promote safe and responsible drone ... efforts. , AMA and DJI will collaborate on other potential opportunities to mutually ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting a ... held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers ... an opportunity to interact with peers, make new connections and talk bio biz. , ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
Breaking Biology Technology:
(Date:1/21/2017)... Research and Markets has announced the addition of the ... offering. ... global voice recognition biometrics market to grow at a CAGR of ... the present scenario and the growth prospects of the global voice ... report considers the revenue generated from the sales of voice recognition ...
(Date:1/18/2017)... Md. , Jan. 18, 2017  In vitro ... respect to mergers and acquisitions (M&A), and Kalorama Information ... for such acquisitions have been shifting. Generally, uncertainty in ... and the U.S. has changed the acquisitions landscape. ... has resulted in companies buying partners outside of their ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
Breaking Biology News(10 mins):